Latest News

Break Wave lithotripsy's real-time ultrasound visualization of cavitation and its low-energy resonant frequency delivery mechanistically reduce the risk of renal hematoma and arrhythmia seen with conventional shock wave lithotripsy, while the boundaries of stone size, Hounsfield unit thresholds, and patient anatomy eligible for treatment remain to be defined in commercial practice, according to Ben H. Chew, MD, MSc, FRCSC.

This decision marks the first approval of a PD-1 inhibitor plus antibody-drug conjugate regimen in the EU.

Fred Saad, MD, CQ, FRCS, FCAHS, discusses additional efficacy data from the phase 3 PSMAddition trial, evaluating the addition of 177Lu-PSMA-617 to standard of care ADT plus an ARPI in PMSA+ mHSPC.

Mina M. Fam, MD, discusses the significance of the FDA's recent approval of tebipenem pivoxil for patients with complicated urinary tract infections.

Enzalutamide plus talazoparib showed promising clinical activity in high-volume mHSPC, although with a notable toxicity burden.

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, is joined by Larry Lipshultz, MD, and Rachel Rubin, MD, for a conversation on advocacy, sexual medicine, and the evolving role of urologists in women’s health.

Rahul Winayak, MD, discusses the prognostic and predictive value of microbial dysbiosis in patients receiving CBM588 plus first-line immune checkpoint inhibitor-based regimens for metastatic renal cell carcinoma.

Eugene Pietzak, MD, highlights results from a phase 2 study of pembrolizumab plus BCG for patients with very high-risk, BCG-naive high-grade T1 NMIBC who declined upfront radical cystectomy.

Preston C. Sprenkle, MD, discusses the unmet needs, emerging solutions, and longer-term vision for MRI in prostate cancer care.

Sandip Prasad, MD, discusses 3-year data from the phase 3 ENVISION trial evaluating mitomycin for intravesical solution for recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.

In this episode of The UroOnc Minute, Lourdes Guerrios-Rivera, MD, discusses strategies to improve patient engagement and adherence during active surveillance for prostate cancer, highlighting the critical roles of education, communication, and structured follow-up.

The agency is requesting a removal of the limitation of use for age-related hypogonadism as well as updated warnings related to prostate cancer risk and benign prostatic hyperplasia.

Data from the RAMPART trial showed that durvalumab monotherapy missed the DFS threshold in resected RCC, though the combination with tremelimumab showed significant benefit.